vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and iQSTEL Inc (IQST). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $84.2M, roughly 1.0× iQSTEL Inc). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -14.9%). iQSTEL Inc produced more free cash flow last quarter ($-1.2M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 28.0%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
iQSTEL Inc is a technology holding company operating three core segments: telecommunications, Internet of Things (IoT), and fintech. It offers connectivity services, smart IoT monitoring solutions, and digital financial tools, mainly serving small and medium-sized enterprises and retail customers in North and South American markets.
IOVA vs IQST — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $84.2M |
| Net Profit | — | $-2.7M |
| Gross Margin | 67.4% | 3.5% |
| Operating Margin | -84.7% | -2.9% |
| Net Margin | — | -3.2% |
| Revenue YoY | 17.7% | -14.9% |
| Net Profit YoY | — | -44.5% |
| EPS (diluted) | — | $-0.92 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $84.2M | ||
| Q3 25 | $67.5M | $102.9M | ||
| Q2 25 | $60.0M | $72.2M | ||
| Q1 25 | $49.3M | $57.6M | ||
| Q4 24 | $73.7M | $98.9M | ||
| Q3 24 | $58.6M | $54.2M | ||
| Q2 24 | $31.1M | $78.6M | ||
| Q1 24 | $715.0K | $51.4M |
| Q4 25 | — | $-2.7M | ||
| Q3 25 | $-91.3M | $-2.3M | ||
| Q2 25 | $-111.7M | $-2.3M | ||
| Q1 25 | $-116.2M | $-1.1M | ||
| Q4 24 | — | $-1.9M | ||
| Q3 24 | $-83.5M | $-773.0K | ||
| Q2 24 | $-97.1M | $-2.0M | ||
| Q1 24 | $-113.0M | $-580.2K |
| Q4 25 | 67.4% | 3.5% | ||
| Q3 25 | 43.0% | 2.7% | ||
| Q2 25 | 5.5% | 2.6% | ||
| Q1 25 | -0.8% | 3.4% | ||
| Q4 24 | 68.7% | 2.7% | ||
| Q3 24 | 46.2% | 3.7% | ||
| Q2 24 | -0.8% | 2.8% | ||
| Q1 24 | — | 2.7% |
| Q4 25 | -84.7% | -2.9% | ||
| Q3 25 | -140.7% | -0.5% | ||
| Q2 25 | -189.8% | -0.9% | ||
| Q1 25 | -245.8% | -1.0% | ||
| Q4 24 | -117.5% | -0.3% | ||
| Q3 24 | -152.1% | -0.1% | ||
| Q2 24 | -327.6% | -0.4% | ||
| Q1 24 | -16464.6% | -0.4% |
| Q4 25 | — | -3.2% | ||
| Q3 25 | -135.3% | -2.3% | ||
| Q2 25 | -186.2% | -3.3% | ||
| Q1 25 | -235.5% | -2.0% | ||
| Q4 24 | — | -1.9% | ||
| Q3 24 | -142.7% | -1.4% | ||
| Q2 24 | -312.2% | -2.5% | ||
| Q1 24 | -15800.8% | -1.1% |
| Q4 25 | — | $-0.92 | ||
| Q3 25 | — | $-0.68 | ||
| Q2 25 | $-0.33 | $-0.82 | ||
| Q1 25 | $-0.36 | $-0.44 | ||
| Q4 24 | $-0.24 | $-1.19 | ||
| Q3 24 | $-0.28 | $-0.40 | ||
| Q2 24 | $-0.34 | $-0.90 | ||
| Q1 24 | $-0.42 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $2.2M |
| Total DebtLower is stronger | — | $4.1M |
| Stockholders' EquityBook value | $698.6M | $16.3M |
| Total Assets | $913.2M | $51.1M |
| Debt / EquityLower = less leverage | — | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $2.2M | ||
| Q3 25 | $300.8M | $2.3M | ||
| Q2 25 | $301.2M | $2.0M | ||
| Q1 25 | $359.7M | $1.1M | ||
| Q4 24 | $323.8M | $2.5M | ||
| Q3 24 | $397.5M | $2.1M | ||
| Q2 24 | $412.5M | $797.2K | ||
| Q1 24 | $356.2M | $2.7M |
| Q4 25 | — | $4.1M | ||
| Q3 25 | — | $2.7M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $3.5M | ||
| Q4 24 | — | $2.5M | ||
| Q3 24 | — | $3.2M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $194.0K |
| Q4 25 | $698.6M | $16.3M | ||
| Q3 25 | $702.3M | $17.9M | ||
| Q2 25 | $698.5M | $14.3M | ||
| Q1 25 | $767.9M | $11.6M | ||
| Q4 24 | $710.4M | $11.9M | ||
| Q3 24 | $773.5M | $8.1M | ||
| Q2 24 | $768.5M | $7.6M | ||
| Q1 24 | $680.0M | $8.4M |
| Q4 25 | $913.2M | $51.1M | ||
| Q3 25 | $904.9M | $46.9M | ||
| Q2 25 | $907.4M | $51.4M | ||
| Q1 25 | $966.7M | $42.0M | ||
| Q4 24 | $910.4M | $79.0M | ||
| Q3 24 | $991.1M | $32.4M | ||
| Q2 24 | $964.3M | $30.0M | ||
| Q1 24 | $869.8M | $22.1M |
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.31× | ||
| Q1 25 | — | 0.31× | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | 0.40× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-1.2M |
| Free Cash FlowOCF − Capex | $-61.9M | $-1.2M |
| FCF MarginFCF / Revenue | -71.3% | -1.5% |
| Capex IntensityCapex / Revenue | 10.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $-4.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-1.2M | ||
| Q3 25 | $-78.7M | $-953.0K | ||
| Q2 25 | $-67.4M | $257.7K | ||
| Q1 25 | $-103.7M | $-1.9M | ||
| Q4 24 | $-73.3M | $-403.7K | ||
| Q3 24 | $-59.0M | $625.0K | ||
| Q2 24 | $-98.4M | $-2.6M | ||
| Q1 24 | $-122.3M | $-536.9K |
| Q4 25 | $-61.9M | $-1.2M | ||
| Q3 25 | $-89.5M | $-969.2K | ||
| Q2 25 | $-74.9M | $211.7K | ||
| Q1 25 | $-109.9M | $-2.0M | ||
| Q4 24 | $-77.5M | $-421.3K | ||
| Q3 24 | $-61.3M | $594.5K | ||
| Q2 24 | $-98.9M | $-2.6M | ||
| Q1 24 | $-126.5M | $-608.5K |
| Q4 25 | -71.3% | -1.5% | ||
| Q3 25 | -132.7% | -0.9% | ||
| Q2 25 | -124.9% | 0.3% | ||
| Q1 25 | -222.8% | -3.4% | ||
| Q4 24 | -105.1% | -0.4% | ||
| Q3 24 | -104.6% | 1.1% | ||
| Q2 24 | -317.9% | -3.4% | ||
| Q1 24 | -17685.3% | -1.2% |
| Q4 25 | 10.7% | 0.0% | ||
| Q3 25 | 16.1% | 0.0% | ||
| Q2 25 | 12.4% | 0.1% | ||
| Q1 25 | 12.6% | 0.1% | ||
| Q4 24 | 5.7% | 0.0% | ||
| Q3 24 | 3.9% | 0.1% | ||
| Q2 24 | 1.4% | 0.0% | ||
| Q1 24 | 583.4% | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
IQST
| USA | $53.2M | 63% |
| Other | $29.9M | 35% |
| Switzerland | $1.1M | 1% |
